nach oben

Erschienen in:

30.11.2021 | Mammakarzinom | Algorithmus und Klassifikation

Therapiealgorithmen für das Mammakarzinom

verfasst von: Univ.-Prof. Dr. med. J.-U. Blohmer, A. Schneeweiss, I. Bauerfeind, T. Fehm, V. Müller, C. Thomssen, I. Witzel, A. Wöckel, W. Janni

Erschienen in: Die Onkologie | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Auszug

Die Therapiealgorithmen wurden mit Zustimmung der AGO Kommission Mamma übernommen. Lediglich die graphischen Darstellungen wurden modifiziert. Die Inhalte blieben unverändert. Weitere Therapieempfehlungen finden Sie unter www.ago-online.de. Die Therapiealgorithmen für die verschiedenen Konstellationen des Mammakarzinoms sind mit dazugehöriger Legende (Abb. 1) in den Abb. 2, 3, 4, 5, 6, 7, 8, 9 und 10 dargestellt. …

Reimer T, Gerber B (2010) Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly. Drugs Aging 27(10):791–800PubMedCrossRef

Tuttle TM, Shamliyan T, Virnig BA et al (2010) The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010(41):117–120 (Review)PubMedPubMedCentralCrossRef

Gerber B, Heintze K, Stubert J et al (2011) Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today? Breast Cancer Res Treat 128(3):613–624PubMedCrossRef

D’Angelo-Donovan DD, Dickson-Witmer D, Petrelli NJ (2012) Sentinel lymph node biopsy in breast cancer: a history and current clinical recommendations. Surg Oncol 9:196-200. https://doi.org/10.1016/j.suronc.2011.12.005CrossRef

Galimberti V, Cole BF, Zurrida S et al (2013) International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305PubMedPubMedCentralCrossRef

Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318(10):918–926PubMedPubMedCentralCrossRef

Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective multi-center cohort study. Lancet Oncol 14(7):609–618PubMedCrossRef

Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461PubMedPubMedCentralCrossRef

Fu JF, Chen HL, Yang J et al (2014) Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS ONE 9(9):e105316PubMedPubMedCentralCrossRef

10.

Lee HD, Ahn SG, Lee SA et al (2014) Prospective evaluation of the feasibility of sentinel lymph node biopsy in breast cancer patients with negative axillary conversion after neoadjuvant chemotherapy. Cancer Res Treat. https://doi.org/10.4143/crt.2013.208CrossRefPubMedPubMedCentral

11.

Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258–264PubMedCrossRef

12.

Boughey JC, Ballman KV, Le-Petross HAT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive Neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg 263(4):802–807. https://doi.org/10.1097/SLA.0000000000001375CrossRefPubMed

13.

Ryu JM, Lee SK, Kim JY et al (2017) Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy: nomogram for predicting Nonsentinel lymph node metastasis. Clin Breast Cancer 17(7):550–555PubMedCrossRef

14.

Galimberti V, Ribeiro Fontana SK, Maisonneuve P (2016) Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 42(3):361–368PubMedCrossRef

15.

Martelli G, Miceli R, Folli S et al (2017) Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: long-term results of a retrospective study. Eur J Surg Oncol 43(11):2012–2020PubMedCrossRef

16.

Palmer JAV, Flippo-Morton T, Walsh KK et al (2018) Application of ACOSOG Z1071: effect of results on patient care and surgical decision-making. Clin Breast Cancer. 18(4):270–275. https://doi.org/10.1016/j.clbc.2017.10.006CrossRefPubMed

17.

Fernandez-Gonzalez S, Falo C, Pla MJ et al (2017) The shift from sentinel lymph node biopsy performed either before or after neoadjuvant systemic therapy in the clinical negative nodes of breast cancer patients. Results, and the advantages and disadvantages of both procedures. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2017.08.014CrossRefPubMed

18.

Classe JM, Loaec C, Gimbergues P et al (2018) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-5004-7CrossRefPubMed

19.

Tee SR, Devane LA, Evoy D et al (2018) Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg 105(12):1541–1552PubMedCrossRef

20.

Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N (2019) St. Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 14(2):103–110PubMedPubMedCentralCrossRef

21.

Classe JM, Loaec C, Gimbergues P et al (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 173(2):343–352PubMedCrossRef

22.

Allweis TM, Menes T, Rotbart N et al (2020) Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery. Eur J Surg Oncol 46(6):1041–1045. https://doi.org/10.1016/j.ejso.2019.11.501CrossRefPubMed

23.

Balasubramian R, Morgan C, Shaari E et al (2020) Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy. Eur J Surg Oncol 46(6):1028–1033. https://doi.org/10.1016/j.ejso.2019.12.007CrossRef

24.

Coufal O, Zapletal O, Gabrielová L et al (2018) Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy—a retrospective study. Rozhl Chir 97(12):551–557PubMed

25.

Ditsch N, Rubio IT, Gasparri ML et al (2020) Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019. Curr Opin Obstet Gynecol 32(1):91–99PubMedCrossRef

26.

Flores-Funes D, Aguilar-Jiménez J, Martínez-Gálvez M et al (2019) Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: preliminary results. Surg Oncol 30:52–57. https://doi.org/10.1016/j.suronc.2019.05.019CrossRefPubMed

27.

Gandhi A, Coles C, Makris A et al (2019) Axillary surgery following neoadjuvant chemotherapy—multidisciplinary guidance from the association of breast surgery, faculty of clinical oncology of the royal college of radiologists, UK breast cancer group, national coordinating committee for breast pathology and British society of breast radiology. Clin Oncol 31(9):664–668CrossRef

28.

García-Moreno JL, Benjumeda-Gonzalez AM, Amerigo-Góngora M et al (2019) Targeted axillary dissection in breast cancer by marking lymph node metastasis with a magnetic seed before starting neoadjuvant treatment. J Surg Case Rep 2019(11):rjz344PubMedPubMedCentralCrossRef

29.

Greenwood HI, Wong JM, Mukhtar RA et al (2019) Feasibility of magnetic seeds for preoperative localization of axillary lymph nodes in breast cancer treatment. AJR Am J Roentgenol 213(4):953–957PubMedCrossRef

30.

Hellingman D, Donswijk ML, Winter-Warnars GAO et al (2019) Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy. EJNMMI Res 9(1):94PubMedPubMedCentralCrossRef

31.

Kanesalingam K, Sriram N, Heilat G et al (2019) Targeted axillary dissection after neoadjuvant systemic therapy in patients with node-positive breast cancer. ANZ J Surg. https://doi.org/10.1111/ans.15604CrossRefPubMed

32.

Natsiopoulos I, Intzes S, Liappis T et al (2019) Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cN+ before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer 19(3):208–215PubMedCrossRef

33.

Simons JM, van Nijnatten TJA, van der Pol CC et al (2019) Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 269(3):432–442PubMedCrossRef

34.

Simons JM, van Pelt MLMA, Marinelli AWKS et al (2019) Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer. Br J Surg 106(12):1632–1639PubMedPubMedCentralCrossRef

35.

36.

Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N (2021) AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 81(10):1112–1120PubMedPubMedCentralCrossRef

37.

El-Sabawi B et al (2016) Radiation and breast reconstruction: algorithmic approach and evidence-based outcomes. J Surg Oncol 113(8):906–912PubMedCrossRef

38.

Gerber B et al (2015) Breast reconstruction following cancer treatment. Dtsch Arztebl Int 112(35–36):593–600PubMedPubMedCentral

39.

Kuerer H et al (2017) Optimizing breast cancer adjuvant radiation and integration of breast and reconstructive surgery. ASCO Educational Book. Memorial Sloan Kettering Cancer Center, Fig. 2 und 3CrossRef

40.

Cordeiro P et al (2015) What is the optimum timing of postmastectomy radiotherapy in two-stage prosthetic reconstruction: radiation to the tissue expanderor permanent implant? Plast Reconstr Surg 135(6):1509–1517. https://doi.org/10.1097/PRS.0000000000001278CrossRefPubMedPubMedCentral

41.

Bennett KG, Qi J, Kim HM et al (2018) Comparison of 2‑year complication rates among common techniques for postmastectomy breast reconstruction. JAMA Surg 153(10):901–908. https://doi.org/10.1001/jamasurg.2018.1687CrossRefPubMedPubMedCentral

42.

He WY et al (2020) Complications and patient-reported outcomes after TRAM and DIEP flaps: a systematic review and meta-analysis. Plast Reconstr Surg Glob Open 8(10):e3120. https://doi.org/10.1097/GOX.0000000000003120CrossRefPubMedPubMedCentral

43.

Gianni L et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32PubMedCrossRef

44.

Tolaney SM et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2‑positive breast cancer. J Clin Oncol 37(22):1868–1875PubMedPubMedCentralCrossRef

45.

Perez EA et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2‑positive breast cancer: planned joint analysis of overall survival from NSABP B‑31 and NCCTG N9831. J Clin Oncol 32:3744–3752PubMedPubMedCentralCrossRef

46.

Herceptin Adjuvant (HERA) Trial Study Team, Cameron D et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205CrossRef

47.

Martin M et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5‑year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700PubMedCrossRef

48.

APHINITY Steering Committee and Investigators, von Minckwitz G et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131CrossRef

49.

Piccart M, et al. Interim overall survival analysis of APHINITY (BIG 4–11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019; abstr. GS 01–04

50.

Gianni L et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15:640PubMedCrossRef

51.

von Minckwitz G et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617–628CrossRef

52.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J (2018) Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89:27–35PubMedCrossRef

53.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784CrossRef

54.

Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–806PubMedPubMedCentralCrossRef

55.

Francis PA, Regan MM, Fleming GF et al (2015) The SOFT Investigators and the International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446PubMedCrossRef

56.

Pagani O, Regan MM, Walley BA et al. TEXT and SOFT Investigators, International Breast Cancer Study Group (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118PubMedPubMedCentralCrossRef

57.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784CrossRef

58.

59.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352CrossRef

60.

Gray R (EBCTCG) et al (2018) Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS 2018; GS3-03

61.

Qi WX, Tang LN, He AN et al (2013) Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials. Breast 22(3):314–319PubMedCrossRef

62.

Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO), Belfiglio M, Fanizza C, Tinari N et al (2012) Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol 138(2):221–229CrossRef

63.

Pallis AG, Boukovinas I, Ardavanis A et al (2012) A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 23(5):1164–1169PubMedCrossRef

64.

Dear RF, McGeechan K, Jenkins MC et al (2013) Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 18(12):CD8792. https://doi.org/10.1002/14651858.CD008792.pubCrossRef

65.

Petrelli F, Ghidini A, Pedersini R et al (2019) Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat 174(3):597–604. https://doi.org/10.1007/s10549-019-05133-yCrossRefPubMed

66.

ossi V, Berchialla P, Giannarelli D et al (2019) Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers 11(11):E1661. https://doi.org/10.3390/cancers11111661CrossRef

67.

Robson M et al (2017) Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med 377(6):523–533PubMedCrossRef

68.

Robson ME, Tung N, Conte P et al (2019) OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30(4):558–566. https://doi.org/10.1093/annonc/mdz012CrossRefPubMedPubMedCentral

69.

Robson M, Ruddy KJ, Im SA et al (2019) Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer 120:20–30. https://doi.org/10.1016/j.ejca.2019.06.023CrossRefPubMedPubMedCentral

70.

Litton J et al (2018) Talazoparib in patients with advanced breast cancer and a Germline BRCA mutation. N Engl J Med 379:753763. https://doi.org/10.1056/NEJMoa180290510CrossRef

71.

ABRAZO Study Group, Turner NC, Telli ML, Rugo HS et al (2019) A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and Germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res 25(9):2717–2724. https://doi.org/10.1158/1078-0432.CCR-18-1891CrossRef

72.

Ettl J, Quek RGW, Lee KH et al (2018) Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 29(9):1939–1947. https://doi.org/10.1093/annonc/mdy257CrossRefPubMed

73.

Hurvitz SA, Gonçalves A, Rugo HS et al (2019) Talazoparib in patients with a Germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial. Oncologist. https://doi.org/10.1634/theoncologist.2019-0493CrossRefPubMedPubMedCentral

74.

Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 29(8):1634–1657PubMedCrossRef

75.

Kornblum NS et al (2016) PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy. SABCS 2016,#S1-02.

76.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, SOLAR‑1 Study Group (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929–1940PubMedCrossRef

77.

Turner N et al (2015) Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 373:209–219PubMedCrossRef

78.

Loibl S et al (2017) Palbociclib combined with Ffulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA‑3 results. Oncologist 22(9):1028–1038PubMedPubMedCentralCrossRef

79.

Layman RM et al (2019) Comparative effectiveness of palbociclib plus letrozole vs. letrozole for metastatic breast cancer in US-real world clinical practises. ESMO, #329P.

80.

Tripathy D et al (2017) First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA‑7 trial. SABCS 2017, GS-26.

81.

Im SA, Lu YS, Bardia A et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307–316. https://doi.org/10.1056/NEJMoa1903765CrossRefPubMed

82.

Sledge GW Jr, Toi M, Neven P et al (2019) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.4782CrossRefPubMedCentral

83.

Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19(2):343–353PubMedCrossRef

84.

Rugo HS et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 34(25):3069–3103PubMedCrossRef

85.

Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90(3):590–594PubMedPubMedCentralCrossRef

86.

Park IH, Ro J, Lee KS et al (2010) Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 28(16):2705–2711PubMedCrossRef

87.

Carlson RW et al (2010) Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28(25):3917–3921PubMedCrossRef

88.

Bartsch R, Bago-Horvath Z et al (2012) Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 48:1932–1938PubMedCrossRef

89.

Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16:994–999PubMedCrossRef

90.

Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609–1618. https://doi.org/10.1056/NEJM199811263392207CrossRefPubMed

91.

Crump M, Sawka CA, DeBoer G et al (1997) An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44:201–210PubMedCrossRef

92.

Finn RS et al (2016) Palbociclib and Letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936PubMedCrossRef

93.

Finn RS et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35PubMedCrossRef

94.

Im SA, Mukai H, Park IH et al (2019) Palbociclib plus Letrozole as first-line therapy in postmenopausal asian women with metastatic breast cancer: results from the phase III, randomized PALOMA‑2 study. J Glob Oncol 5:1–19. https://doi.org/10.1200/JGO.18.00173CrossRefPubMed

95.

Rugo HS, Finn RS, Diéras V et al (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2‑negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174(3):719729. https://doi.org/10.1007/s10549-018-05125-4CrossRef

96.

Hortobagyi GN et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):17381748CrossRef

97.

Yardley DA, Hart L, Favret A et al (2019) Efficacy and safety of Ribociclib with Letrozole in US patients enrolled in the MONALEESA‑2 study. Clin Breast Cancer 19(4):268–277.e1. https://doi.org/10.1016/j.clbc.2019.02.007CrossRefPubMed

98.

Goetz MP et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638–3646PubMedCrossRef

99.

Johnston S, Martin M, Di Leo A et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https://doi.org/10.1038/s41523-018-0097-zCrossRefPubMedPubMedCentral

100.

Bonneterre J et al (2000) Anastrozole versus Tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18:3748–3757PubMedCrossRef

101.

Thürlimann B et al (2004) Anastrozole (Arimidex) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95—a substudy of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85:247–254PubMedCrossRef

102.

Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee; Investigators Committee Members (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247–2258

103.

Mouridsen H et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group Journal of Clinical Oncology. J Clin Oncol 21(11):2101–2109PubMedCrossRef

104.

Paridaens R et al (2003) European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14(9):1391–1398PubMedCrossRef

105.

Xu HB, Liu YJ, Li L (2011) Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis. Clin Breast Cancer 11(4):246–251. https://doi.org/10.1016/j.clbc.2011.06.003CrossRefPubMed

106.

PALOMA3 Study Group, Turner NC, Ro J, André F et al (2015) Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 373(3):209–219CrossRef

107.

Turner NC et al (2018) Overall survival with palbociclib and Fulvestrant in advanced breast cancer. N Engl J Med 379:1926–1936. https://doi.org/10.1056/NEJMoa1810527CrossRefPubMed

108.

Slamon DJ, Neven P, Chia S et al (2018) Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2‑negative advanced breast cancer: MONALEESA‑3. J Clin Oncol 36(24):2465–2472. https://doi.org/10.1200/JCO.2018.78.9909CrossRefPubMed

109.

Slamon DJ, Neven P, Chia S et al (2019) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1911149CrossRefPubMed

110.

Sledge GW Jr et al (2017) MONARCH 2: abemaciclib in combination with Fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875–2884PubMedCrossRef

111.

112.

Ellis MJ et al (2015) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33(32):3781–3787PubMedPubMedCentralCrossRef

113.

Robertson JF et al (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388(10063):2997–3005PubMedCrossRef

114.

Di Leo A et al (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106(1):djt337PubMedCrossRef

115.

CLEOPATRA Study Group, Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734CrossRef

116.

Perez EA, López-Vega JM, Petit T et al (2016) Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res 18(1):126PubMedPubMedCentralCrossRef

117.

Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791PubMedPubMedCentralCrossRef

118.

Krop IE, Lin NU, Blackwell K et al (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26(1):113–119PubMedCrossRef

119.

Murthy RK, Loi S, Okines A et al (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609PubMedCrossRef

120.

Lin NU, Borges V, Anders C et al (2020) Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 38(23):2610–2619PubMedPubMedCentralCrossRef

121.

Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543PubMedCrossRef

122.

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743PubMedCrossRef

123.

Saura C, Oliveira M, Feng Y‑H et al (2020) Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 38(27):3138–3149PubMedPubMedCentralCrossRef

124.

Modi S, Saura C, Yamashita T et al (2020) Trastuzumab-Deruxtecan in previously treated HER2-positive breast cancer. N Eng J Med. https://doi.org/10.1056/NEJMoa1914510CrossRef

125.

von Minckwitz G, Schwedler K, Schmidt M, BIG 03-05 study group and participating investigators et al (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3‑05 phase III study in HER2-positive breast cancer. Eur J Cancer 47(15):2273–2281CrossRef

126.

Rimawi M, Ferrero J‑M, La de Haba-Rodriguez J et al (2018) First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2‑positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36(28):2826–2828PubMedCrossRef

127.

Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2‑positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585–2592PubMedCrossRef

128.

Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28(7):1124–1130PubMedCrossRef

129.

Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2‑positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099PubMedPubMedCentralCrossRef

130.

Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2‑positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529–5537PubMedCrossRef

131.

Huober J, Fasching PA, Barsoum M et al (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer—results of the eLEcTRA trial. Breast 21(1):27–33PubMedCrossRef

132.

Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33):5538–5546PubMedCrossRef

133.

Burstein HJ, Cirrincione CT, Barry WT et al (2014) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of Fulvestrant with or without Lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (alliance). J Clin Oncol 32:3959–3966PubMedPubMedCentralCrossRef

134.

PERTAIN Study Group, Rimawi M, Ferrero JM, de la Haba-Rodriguez J et al (2018) First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2‑positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36(28):2826–2835. https://doi.org/10.1200/JCO.2017.76.7863CrossRef

135.

Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol 29(8):1634–1657PubMedCrossRef

136.

Condorelli R, Mosele F, Verret B et al (2019) Genomic alterations breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 30:365–373PubMedCrossRef

137.

Hu XC, Zhang J, Xu BH et al (2015) Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16(4):436–446PubMedCrossRef

138.

Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a Germline BRCA mutation. N Engl J Med 379(8):753–763PubMedCrossRef

139.

Miles DW, Diéras V, Cortés J et al (2013) First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24(11):2773–2780PubMedCrossRef

140.

Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676PubMedCrossRef

141.

Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799PubMedCrossRef

142.

Robson M, Im S‑A, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med 377:523–533PubMedCrossRef

143.

Robson M, Tung N, Conte P et al (2019) Qlympia AD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metasttic breast cancer. Ann Oncol 30:558–566PubMedPubMedCentralCrossRef

144.

Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121PubMedCrossRef

145.

Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828PubMedCrossRef

146.

Tutt A, Tovey H, Cheang MCU et al (2018) Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24(5):628–637PubMedPubMedCentralCrossRef

147.

Twelves C, Cortes J, Vahdat L et al (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [published correction appears in Breast Cancer Res Treat. 2015 Jan;149(1):313]. Breast Cancer Res Treat 148(3):553–561PubMedPubMedCentralCrossRef

148.

Yardley DA, Coleman R, Conte P et al (2018) nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol 29(8):1763–1770PubMedPubMedCentralCrossRef

149.

TURANDOT investigators, Zielinski C, Láng I, Inbar M et al (2016) Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, noninferiority, phase 3 trial. Lancet Oncol 17(9):1230–1239CrossRef

150.

Bardia A, Tolaney SM, Loirat D et al (2020) ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann Oncol 31(suppl_4):S1142–S1215. https://doi.org/10.1016/annonc/annonc325CrossRef

151.

Bardia A, Mayer IA, Vahdat LT et al (2019) Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380(8):741–751PubMedCrossRef

Titel: Therapiealgorithmen für das Mammakarzinom
verfasst von: Univ.-Prof. Dr. med. J.-U. Blohmer
A. Schneeweiss
I. Bauerfeind
T. Fehm
V. Müller
C. Thomssen
I. Witzel
A. Wöckel
W. Janni
Publikationsdatum: 30.11.2021
Verlag: Springer Medizin
Schlagwörter: Mammakarzinom
Zytostatische Therapie
Mammakarzinom
Lymphadenektomie
Mastektomie
Neratinib
Trastuzumab
Trastuzumab Emtansin
Pertuzumab
Fulvestrant
Tamoxifen
Letrozol
Erschienen in: Die Onkologie / Ausgabe 12/2021
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-021-01060-0

Passend zum Thema

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.

Weitere Lesetipps

Brustkrebs: "Eine weitere Therapieoption, um die endokrine Resistenz zu überwinden“

Spagat zwischen Leitlinien und klinischem Alltag

Herausforderungen und Management krebsassoziierter Thrombosen

CME: Anale Notfälle – Schmerzen

CAT: Was tun bei Lücken in der Evidenz

Präoperative Therapie des Rektumkarzinoms - kritische Anmerkungen zur PROSPECT-Studie

Bildnachweise

AGO Therapiestrategien HR-positives/HER2-negatives, metastasiertes Mammakarzinom/© Springer Medizin Verlag GmbH, Bei Immuntherapien das erhöhte Thromboserisiko beachten /© Leo Pharma GmbH, CAT-Management ist ganz einfach – oder doch nicht?/© LEO Pharma GmbH, Thrombus und Patientin im Gespräch/© crevis / adobe.stock.com (Symbolbild mit Fotomodell), Brustkrebsschleife auf rosa-pinkem Hintergrund/© filo | iStock, Pfeil auf Zielscheibe/© Kunakorn Rassadornyindee | iStock, Schematische Darstellung der weiblichen Brust/© iStock.com | peterschreiber.media, Prof Klamroth/© Leo Pharma GmbH, Krankenhauspharmazie/© Leo Pharma GmbH, Interview Prof. Beyer Westendorf/© LEO Pharma, CAT-Management - Was gibt es Neues bei den NMH/© Leo Pharma GmbH, CAT: Was tun bei Lücken in der Evidenz/© Leo Pharma GmbH, c/© LEO Pharma GmbH, Ärztin misst Blutdruck bei Senior/© Drazen / Stock.adobe.com (Symbolbild mit Fotomodellen), Adenokarzinom des Magens/© jxfzsy / Getty Images / iStock, Arbeiter pustet Maschinenstaub und Dreck von Werkzeug/© dragana991 / Getty Images / iStock (Symbolbild mit Fotomodell), Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Frau mit Kopftuch und Infusion/© FatCamera / Getty Images / iStock (Symbolbild mit Fotomodell), Endoskopisches Bild eines Kolonkarzinoms/© Mehdorn M et al. / all rights reserved Springer Medizin Verlag GmbH, Brustbestrahlung/© Lange T et al. / all rights reserved Springer Medizin Verlag GmbH, Ga-PSMA-PET MRT Verdacht auf Prostatakarzinom/© Springer Medizin Verlag GmbH, Ekzem an der Brustwarze/© T. Jansen, NSCLC Adenokarzinom mit EGFR-Mutation und TTF-1-Positivität/© Tapia, C. et al. / all rights reserved Springer Medizin Verlag GmbH, Ältere Frau schluckt Tablette/© David Pereiras / stock.adobe.com (Symbolbild mit Fotomodellen), Patientin schaut besorgt auf Infusionsbeutel/© KatarzynaBialasiewicz / Getty Images / iStock (Symbolbild mit Fotomodellen), Ältere Frau im Gespräch mit ihrer Ärztin/© pucko_ns / stock.adobe.com (Symbolbild mit Fotomodell), Frau mit Kopftuch sitzt auf Krankenhausbett/© (M) LIGHTFIELD STUDIOS / stock.adobe.com (Symbolbild mit Fotomodell), Zeichen einer Rechtsherzbelastung bei Lungenembolie/© Hobohm L, et al. / all rights reserved Springer Medizin Verlag GmbH, Pflanzliches Arzneimittel/© Chariclo / Fotolia, Drei Patienten mit idealen Befunden für Salvage-Lymphadenektomie./© Horn, T. et al. / all rights reserved Springer Medizin Verlag GmbH, CT: fulminante Lungenarterienembolie/© Staab B et al. / all rights reserved Springer Medizin Verlag GmbH, Arzt zeigt Patient eine Grafik auf dem Tablet/© Pixel-Shot / stock.adobe.com (Symbolbild mit Fotomodellen), Ärztin kontrolliert Infusionssystem/© Wasan / stock.adobe.com (Symbolbild mit Fotomodell), Radiochirurgie: Hirnmetastase eines nichtkleinzelligen Lungenkarzinoms frontal rechts/© Diehl, C., Combs, S.E. / all rights reserved Springer Medizin Verlag GmbH, Ältere Frau mit Tabletten in der Hand/© LIGHTFIELD STUDIOS / stock.adobe.com (Symbolbild mit Fotomodell), Supralevatorischer Abszess in der Computertomographie/© Ommer A et al. / all rights reserved Springer Medizin Verlag GmbH, Lokal fortgeschrittenes Prostatakarzinom/© Preisser & Tilki / all rights reserved Springer Medizin Verlag GmbH, Immunhistochemische Analytik am Beispiel eines kolorektalen Karzinoms./© Büttner, R., Friedrichs, N. / all rights reserved Springer Medizin Verlag GmbH, Scharf begrenzte landkartenartige erythematöse Plaques/© M. Birke et al. / all rights reserved Springer Medizin Verlag GmbH, Postradiogene Morphea/© Stephan R. Künzel und Claudia Günther / all rights reserved Springer Medizin Verlag GmbH, Blutabnahme/© Grafvision / stock.adobe.com (Symbolbild mit Fotomodell), Arzt hält Koloskop/© Graphicroyalty / stock.adobe.com (Symbolbild mit Fotomodell), Metastasierendes nicht-kleinzelliges Lungenkarzinom/© Urushibara M. et al. doi.org/10.1186/s12957-023-02920-2 unter CC-BY 4.0, Infusion/© pix4U / Stock.adobe.com (Symbolbild mit Fotomodell), Operation bei Blasenkrebs/© anistidesign / Fotolia, Ärztin klärt Patientin über Medikamente auf/© auremar / Fotolia (Symbolbild mit Fotomodellen), Beckenvenenthrombose/© Jung et al. / all rights reserved Springer Medizin Verlag GmbH, Short-Segment-Barrett-Ösophagus mit submukosalem Adenokarzinom/© Baumer, S., Pech, O. / all rights reserved Springer Medizin Verlag GmbH, Therapieresistente Brustkrebszellen (in Rot)/© Sheheryar Kabraji und Sridhar Ramaswamy/NCI/cancer.gov, Periphere ulzerative Keratitis (PUK)/© Springer Medizin Verlag GmbH, Ärztin informiert ältere Patientin/© pucko_ns / stock.adobe.com (Symbolbild mit Fotomodellen), Klinisches Bild der Angiosarkome/© Beispiel: Musterfrau M et al. / all rights reserved Springer Medizin Verlag GmbH, Bestrahlungsplan bei Rektumkarzinom/© Springer Medizin Verlag GmbH, Histologische Befunde in der HE-Färbung (a) und PAS-Färbung (b)/© Brommer M. et al. / all rights reserved Springer Medizin Verlag GmbH, Molekulargenetische Testung bei Krebserkrankungen/© Max Kratzer, Intensivstation/© beerkoff / Fotolia (Symbolbild mit Fotomodellen), Person setzt DNS-Probe in Maschine ein/© Vit Kovalcik / stock.adobe.com (Symbolbild mit Fotomodell), Frau erhält Infusion/© Seventyfour / stock.adobe.com (Symbolbild mit Fotomodell), Mit dem MIBI(Multiplexed ion beam imaging)-Mikroskop aufgenommenes kolorektales Karzinom/© Mayer, A., Haist, M. / all rights reserved Springer Medizin Verlag GmbH, Darmpolyp/© Springer Medizin Verlag GmbH

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Bestrahlung bei frühem Mamma-Ca.: Wer, wann, wo, wie lange?

Frühes Mammakarzinom

Cabozantinib für radiojodrefraktäre, differenzierte Schilddrüsenkarzinome

Mammographie-Screening: Eine kritische Bestandsaufnahme

Neoadjuvante, adjuvante und postneoadjuvante Therapiestrategien beim frühen Mammakarzinom zur Eskalation und Deeskalation

Neues zur primär systemischen Therapie des Mammakarzinoms

Passend zum Thema

Passend zum Thema

Weitere Lesetipps